GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmaxis Ltd (OTCPK:PXSLY) » Definitions » Research & Development

Pharmaxis (Pharmaxis) Research & Development : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Pharmaxis Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Pharmaxis's Research & Development for the six months ended in Dec. 2023 was $0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.


Pharmaxis Research & Development Historical Data

The historical data trend for Pharmaxis's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaxis Research & Development Chart

Pharmaxis Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pharmaxis Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Pharmaxis Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmaxis  (OTCPK:PXSLY) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Pharmaxis Research & Development Related Terms

Thank you for viewing the detailed overview of Pharmaxis's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmaxis (Pharmaxis) Business Description

Traded in Other Exchanges
Address
20 Rodborough Road, Locked Bag 5015, Frenchs Forest, Sydney, NSW, AUS, 2086
Syntara Ltd Formerly Pharmaxis Ltd is an Australia based pharmaceutical research company engaged in the research, development, and commercialization of human healthcare products for the treatment and management of fibrotic and inflammatory diseases. The firm's research efforts are focused on discovering drugs to treat inflammatory and fibrotic diseases such as NASH, pulmonary fibrosis, kidney and liver fibrosis and cancer from its amine oxidase inhibitor chemistry platform. Its product pipeline also includes Orbital and ASM8. The operating segments are Mannitol respiratory business and New Drug Development. It generates maximum revenue from Mannitol respiratory business segment.

Pharmaxis (Pharmaxis) Headlines